# Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

> **NCT02625961** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 296 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Pembrolizumab/vibostolimab coformulation
- **BIOLOGICAL:** Favezelimab/pembrolizumab coformulation

## Key facts

- **NCT ID:** NCT02625961
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2025-11-05
- **Final completion:** 2025-11-05
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625961, "Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02625961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*